India News | COVID Positive Anil Vij Shifted to Rohtak's PGIMS, Condition Stable

Rohtak (Haryana) [India], December 14 (ANI): Haryana Home Minister Anil Vij, who had tested positive for coronavirus on December 5, was shifted to the Post-Graduate Institute of Medical Sciences (PGIMS) in Rohtak from Ambala's civil hospital.

According to an official on Sunday, Vij's condition is stable and he has been given a course of Remdesivir. However, doctors will decide on whether he needs to be given plasma therapy.

Also Read | IRCTC Denies ‘Mailing Only Sikhs’ Amidst Farmers’ Protest to Highlight Modi Govt’s Initiatives For The Community.

"State Minister Anil Vij has been admitted to PGIMS Rohtak due to advance symptoms of COVID. His condition is stable. A team of doctors will make a decision on whether he needs to be given plasma therapy. He has been given a course of Remdesivir," Dr Gajendra Singh, a Public Relation Officer, PGIMS Rohtak said.

Vij was the first volunteer for the third phase trial of Covaxin in Haryana last month. He was administered a trial dose of Covaxin at a hospital in Ambala on November 20.

Also Read | Bus Services in Karnataka to Resume from Tomorrow, Says Deputy CM Laxman Savadi After Talks With KSRTC, BMTC Employees Who Went on Strike.

After declaring that he had detected positive for COVID-19, Vij said that he was told by doctors before being administered the first dose during the phase 3 trial of Bharat Biotech's coronavirus vaccine Covaxin that antibodies take 14 days to build in the human body after the second dose.Vij had tweeted that he had received only the first dose of the two-shot coronavirus vaccine developed by Bharat Biotech."Before administering Covaxin, doctors told me that antibodies will develop after 14 days of second dose... I am being treated at a civil hospital and I feel fine. It is only 14 days when I got the first shot," Vij had tweeted in Hindi.He also refuted a media report stating that he did not follow protocol despite being coronavirus positive.

Meanwhile, Bharat Biotech had said in a statement: "Covaxin clinical trials are based on a two-dose schedule, given 28 days apart. The vaccine efficacy will be determined 14 days after the second dose. COVAXIN has been designed to be efficacious when subjects receive both the doses." (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)